

---

# Index

## A

- Abscesses, 62, 116, 125, 129  
Acetylcholine, 16, 19, 80, 103, 156  
Acetylcholine receptor (AChR), 12, 19, 26, 34, 103, 104, 106, 108–111, 172, 181–182  
Acetylcholinesterase, 103, 104  
Acetylcholinesterase inhibitors, 104, 107  
AChR. *See* Acetylcholine receptor (AChR)  
Aciclovir, 127, 128, 136, 161  
Acquired neuromyotonia (NMT), 162  
Active comparator-controlled, 70  
Acute disseminated encephalomyelitis (ADEM), 26, 31, 58, 63, 84  
Acute inflammatory demyelinating polyneuropathy (AIDP), 24, 93, 96–98  
Acute motor and sensory axonal neuropathy (AMSAN), 96  
Acute motor axonal neuropathy (AMAN), 95–97  
Acute multifocal placoid pigment epitheliopathy (AMPPE), 164  
AD. *See* Alzheimer's disease (AD)  
Adalimumab, 11, 170  
ADCC. *See* Antibody-dependent cellular cytotoxicity (ADCC)  
ADEM. *See* Acute disseminated encephalomyelitis (ADEM)  
Adhesion molecules, 3, 13, 32, 76, 89, 99, 100, 130, 157, 169  
Affinity constant, 181, 184  
AIDP. *See* Acute inflammatory demyelinating polyneuropathy (AIDP)  
Alemtuzumab, 35, 168, 171, 197  
Alpha 4-integrin (natalizumab, Tysabri), 13  
 $\alpha$ -synuclein, 156  
ALS. *See* Amyotrophic lateral sclerosis (ALS)  
Alzheimer's disease (AD), 2, 23, 155–156, 173  
Alzheimer's vaccine, 156  
AMAN. *See* Acute motor axonal neuropathy (AMAN)  
Aminoacyl-tRNA synthetases, 113  
4-aminopyridine (Ampyra), 79  
Amphiphysin, 162  
Amphotericin B, 124  
AMPPE. *See* Acute multifocal placoid pigment epitheliopathy (AMPPE)  
AMSAN. *See* Acute motor and sensory axonal neuropathy (AMSAN)  
Amyloid precursor protein (APP), 155  
Amyotrophic lateral sclerosis (ALS), 20, 24, 132, 155  
AN-1792, 156  
ANA. *See* Antinuclear antibodies (ANA)  
ANCA, 144  
Anti-aquaporin 4, 27, 52, 170, 181, 182  
Antibody-dependent cellular cytotoxicity (ADCC), 8, 172  
Anticardiolipin antibodies, 138, 142  
Anti-ganglioside antibodies, 97  
Antigen-presenting cell (APC), 4, 5, 10, 29, 33, 87  
Antigen receptors, 3, 30  
Anti-GQ1b antibodies, 95, 97  
Anti-Hu antibodies, 182  
Anti-Jo-1 antibodies, 113  
Anti-myeloperoxidase (MPO), 144, 148  
Anti-neutrophilic cytoplasmic antibodies, 144  
Anti-NMDA receptor encephalitis, 149, 151  
Antinuclear antibodies (ANA), 145, 180  
Antiphospholipid antibody syndrome (APS), 58, 138, 142–143, 145, 180  
Anti-Purkinje cell, 35, 148  
Anti-Yo antibodies, 149, 182  
APC. *See* Antigen-presenting cell (APC)  
Aphasia, 18, 130  
Apoptose, 85  
Apoptosis, 3, 7, 100, 168  
APP. *See* Amyloid precursor protein (APP)  
APS. *See* Antiphospholipid antibody syndrome (APS)  
Aquaporin-4 receptors, 27, 34, 62  
antibody, 169–170, 172, 181, 182  
in NMO, 180, 181  
Arachnoid mater, 20, 28  
Arachnoid villi, 20  
Argyll Robertson pupils, 138  
Arthrogyrosis multiplex congenital, 109

- ASCVD. *See* Atherosclerotic cerebrovascular disease (ASCVD)
- Aseptic meningitis, 123, 125
- Astrocytes, 17–18, 27, 32, 33, 88, 156, 181
- Astrocytic endfeet, 27, 28, 86
- Ataxia, 17, 22, 65, 97, 149, 152, 161, 184
- Atherosclerotic cerebrovascular disease (ASCVD), 155
- Atherosclerotic plaque, 157
- Atrophy, 23, 24, 39, 42, 46, 52, 53, 106, 111, 129, 152, 155, 157, 184
- Attack(s), 33, 37, 40–46, 50–52, 55, 57, 59, 61, 63, 71, 72, 74, 83, 85, 89, 95, 100, 103, 122, 130, 195
- Axon, 16, 17, 20, 23, 24, 95, 96, 99, 103, 134
- Azathioprine (Imuran), 76–78, 108, 128, 192–194
- B**
- Babinski, 22, 51, 52, 117
- Baclofen, 16, 79
- Bannwarth's syndrome, 122
- Bapineuzumab, 156
- Barré, Jean Alexander, 93
- BBB. *See* Blood–brain barrier (BBB)
- B cell. *See* Bursa-derived cell (B cell)
- B-1 cell, 5
- B-2 cell, 5
- B-cell receptor (BCR), 3–5
- Bcl-2, 3
- BCR. *See* B-cell receptor (BCR)
- Behcet's syndrome, 164
- $\beta$ -amyloid, 155, 156
- Beta-2 glycoprotein, 142
- BFP. *See* Biological false positive (BFP)
- Bickerstaff's brainstem encephalitis, 97
- Biological false positive (BFP), 145, 180
- Biologics, 74, 167, 169, 170, 196–197
- Blood–brain barrier (BBB), 20, 27, 30, 32, 53, 54, 84, 87, 89, 90, 100, 115, 119, 171, 172, 177, 181, 183
- Blood–nerve barrier (BNB), 32, 100
- Blown pupil, 127
- BNB. *See* Blood–nerve barrier (BNB)
- Bordetella pertussis*, 84
- Borrelia afzelii*, 120
- Borrelia burgdorferi*, 2–4, 13, 50, 61, 119–121, 123, 175, 176, 178–180, 186, 190
- Borrelia garinii*, 120
- Bradykinesia, 156
- Brain abscess, 62, 116, 129
- Brainstem, 18, 21, 54, 97, 138, 153, 164
- Bungarotoxin, 104, 172, 181–182
- Bursa-derived cell (B cell), 3–8, 10, 13, 26, 28–31, 33, 54, 77, 88, 98, 110, 130, 153, 168, 169, 172, 177, 185, 187, 190, 191, 195, 197
- Bursa of Fabricius, 4
- C**
- Cadherins, 13
- CAEV. *See* Caprine arthritis encephalitis virus (CAEV)
- Calcineurin, 194
- Calcineurin inhibitors (CNIs), 194
- Camph, 197
- Campylobacter jejuni*, 95
- CAMs. *See* Cell adhesion molecules (CAMs)
- Candida, 7, 33, 188
- Canine distemper virus (CDV), 88, 89
- Caprine arthritis encephalitis virus (CAEV), 87, 89
- Carpal tunnel syndrome, 19
- Caspases, 3
- CBC. *See* Complete blood count (CBC)
- CD. *See* Cluster of differentiation (CD) molecules
- CD3 antigen, 6, 8, 12, 13, 177
- CD4 antigen, 6, 13, 87, 117, 124, 177, 196
- CD8 antigen, 6, 12, 13, 126, 177, 196
- CD19 antigen, 5, 13, 177
- CD20 antigen, 4, 5, 13, 35, 130, 168, 169, 177, 187, 197
- CD25 antigen, 197
- CD52 antigen, 169, 171, 197
- CD56 antigen, 8, 197
- CD59 antigen, 13
- CD106 antigen, 76
- CDMS. *See* Clinically definite MS (CDMS)
- Cell adhesion molecules (CAMs), 13, 76, 100
- Cell body, 16, 17, 27
- Cerebellum, 15, 16, 18, 148, 149, 152
- Cerebrospinal fluid (CSF), 20, 21, 30–32, 35, 54–55, 57–61, 63, 89, 97, 117–125, 127, 128, 131, 138, 143, 146, 152, 160, 161, 163, 164, 170, 175, 177, 180, 183–187
- Cerebrum, 18, 153, 155
- Certolizumab, 11, 170
- CFE. *See* Chronic focal encephalitis (CFE)
- CFS. *See* Chronic fatigue syndrome (CFS)
- Chancre, 137
- Charcot, 22, 38, 53
- Chemokines, 3, 8, 27, 30, 76, 100, 157
- Chickenpox, 136, 161
- Chinese hamster ovary (CHO) cells, 72, 169
- CHO. *See* Chinese hamster ovary (CHO) cells
- Cholecystokinin, 79
- Chorea, 161–162
- Chronic fatigue syndrome (CFS), 179
- Chronic focal encephalitis (CFE), 164
- Chronic inflammatory demyelinating polyneuropathy (CIDP), 24, 26, 98, 196, 197
- Churg-Strauss syndrome, 144
- CIDP. *See* Chronic inflammatory demyelinating polyneuropathy (CIDP)
- CIS. *See* Clinically isolated syndrome (CIS)
- Class II MHC antigens, 8, 30, 39
- Clinically definite MS (CDMS), 41, 57, 71
- Clinically isolated syndrome (CIS), 41, 43, 50, 51, 53–55, 57, 71
- Cluster of differentiation (CD) molecules, 3, 12–13, 177
- CMAP. *See* Compound muscle action potential (CMAP)
- CMV. *See* Cytomegalovirus (CMV)
- CNIs. *See* Calcineurin inhibitors (CNIs)
- CNS toxoplasmosis, 7, 116, 117
- Cobratoxin, 104, 110
- Complement, 3, 8, 10, 13, 97, 100, 103, 121, 156, 168, 196

Complement system, 85, 156  
 Complete blood count (CBC), 31, 51, 177  
 Compound muscle action potential (CMAP), 107  
 Conjugate, 21, 40, 150, 178  
 Conotoxin, 104, 172, 182  
 Coonhound paralysis, 95  
 Copolymer, 75  
 Corticosteroids, 38, 51, 57, 65, 72, 78, 97, 98, 108, 112, 113, 118, 136, 141, 144–146, 150, 152, 153, 163, 164, 189–194  
*Corynebacterium diphtheriae*, 93  
 Cranial nerves, 18, 20, 21, 30, 44, 63, 64, 93, 94, 97, 122, 124, 127, 141–143, 164  
 C-reactive protein (hs-CRP), 158  
 Cryptic antigens, 100  
 Cryptococcal antigen, 180, 187  
 Cryptococcal antigen test, 124  
*Cryptococcus neoformans*, 124  
 CSF. *See* Cerebrospinal fluid (CSF)  
 Cuprizone, 89  
 Cyclophilin, 194  
 Cyclophosphamide (Cytosan), 76–78, 108, 143, 145, 146, 194–195  
 Cyclosporine, 38, 194  
 Cysticercosis, 51, 61, 113, 125, 129, 187  
 Cytokines, 3–6, 8, 11–13, 27, 29, 30, 32, 33, 76, 89, 100, 144, 156, 157, 196  
 Cytomegalovirus (CMV), 7, 13, 130, 179

**D**  
 Daclizumab, 8, 35, 168, 188, 197  
 DADS. *See* Distal acquired demyelinating sensory neuropathy (DADS)  
 Dancing eyes, 150  
 Dancing eyes–dancing feet, 150  
 Dancing feet, 150  
 Dawson, James Walker, 53  
 Dawson's fingers, 53  
 DCs. *See* Dendritic cells (DCs)  
 Deep tendon reflexes (DTRs), 20–22, 44, 51, 95, 97, 106, 108  
 Delayed-type hypersensitivity (DTH), 32, 33, 188  
 Dementia, 25, 33, 63, 65, 128, 149, 155, 157  
 Dementia with Lewy bodies, 157  
 Demyelination, 17, 31, 37, 41, 42, 46, 49, 62, 63, 65, 83, 84, 86–89, 95–97, 100, 121, 126, 141, 159, 160, 170–172  
 Dendritic cells (DCs), 3, 8, 9, 13, 28–30, 85, 111, 157, 171  
 Dendrotoxin, 104, 162, 172, 182  
 Dermatomyositis, 111–114, 150, 152, 196  
 Devic's disease, 62, 170  
 Dilute Russell's viper venom time assay (dRVVT), 142, 143  
 Diphtheria antitoxin, 94  
 Diphtheria toxin, 94  
 Diphtheritic neuropathy (DN), 93, 94  
 Diplopia, 21, 50, 106  
 Disease-modifying drugs (DMDs), 54, 69–78, 196

Distal acquired demyelinating sensory neuropathy (DADS), 99  
 Distemper viruses, 88, 160  
 DMDs. *See* Disease-modifying drugs (DMDs)  
 DN. *See* Diphtheritic neuropathy (DN)  
 Dopamine, 16, 156  
 Dopaminergic neurons, 156  
 Double-blinded, 70  
 dRVVT. *See* Dilute Russell's viper venom time assay (dRVVT)  
 DTH. *See* Delayed-type hypersensitivity (DTH)  
 DTRs. *See* Deep tendon reflexes (DTRs)  
 Dura mater, 20, 28

**E**

EAE. *See* Experimental autoimmune encephalomyelitis (EAE)  
 EAM. *See* Experimental autoimmune myositis (EAM)  
 EAMG. *See* Experimental autoimmune myasthenia gravis (EAMG)  
 EAN. *See* Experimental autoimmune neuritis (EAN)  
 EBV. *See* Epstein–Barr virus (EBV)  
 Echinococcosis, 125  
*Echinococcus*, 129  
*E.coli*, 72, 122  
 EDSS. *See* Expanded disability status scale (EDSS)  
 EEG. *See* Electro-encephalography (EEG)  
 Efalizumab, 130, 137  
 Electric eels, 109  
 Electric organ, 109–110  
 Electro-encephalography (EEG), 23–24, 160  
 Electromyography (EMG), 19, 23–24, 97, 98, 107–109, 112, 133, 134, 162, 163  
 Electromyography and nerve conduction velocity testing, 24, 163  
 ELISA. *See* Enzyme-linked immunosorbent assay (ELISA)  
 Embolus, 157  
 EMEA, 71  
 EMG. *See* Electromyography (EMG)  
 Encephalitis, 21, 26, 32, 88, 89, 97, 121, 125–127, 130–132, 148–152, 159, 164, 172, 179, 182, 187  
 Encephalitogen(s), 75, 84, 85, 100, 171  
 Encephalopathy, 21, 63, 66, 133, 163–164  
 Endomysium, 111  
 Enzyme-linked immunosorbent assay (ELISA), 74, 135, 142, 175, 177–180  
 EOMs. *See* Extraocular muscles (EOMs)  
 Ependymal cells, 20  
 Epinephrine, 16  
 Epstein–Barr virus (EBV), 7, 60, 179  
 Epstein–Barr virus-associated lymphoma, 7  
 Erythema migrans, 122  
 Erythrocyte sedimentation rate (ESR), 31, 113, 144, 177  
 ESR. *See* Erythrocyte sedimentation rate (ESR)  
 Etanercept, 11, 169, 170  
 Exotoxin, 84  
 Expanded disability status scale (EDSS), 22, 40–42, 45, 46  
 Experimental autoimmune encephalomyelitis (EAE), 26, 27, 31, 39, 75, 84–90, 100, 170, 171, 181

Experimental autoimmune myasthenia gravis (EAMG), 26, 27, 109, 110  
 Experimental autoimmune myositis (EAM), 114  
 Experimental autoimmune neuritis (EAN), 26, 27, 93, 100  
 Extraocular muscles (EOMs), 105

**F**

Fab portion, 4, 9, 10, 99, 168  
 FACS. *See* Fluorescence-activated cell sorting (FACS)  
 Famciclovir (Famvir), 136  
 Fampridine, 79  
 Fas ligand, 3  
 Fas receptor, 3  
 Fc receptor, 8–10, 168, 169, 196  
 FDA, 35, 38, 42, 71, 77, 78, 105, 167–169, 171, 196, 197  
 FDG. *See* F-fluorodeoxyglucose (FDG)  
 F-fluorodeoxyglucose (FDG), 158  
 Fibromyalgia, 179  
 Fingolimod, 63, 70, 78, 136, 171, 195–196  
 Fisher, Miller, 95, 96, 100  
 Fisher variant of GBS, 95, 96, 100  
 Flavivirus, 130, 179  
 Flucytosine, 124  
 Fluorescence-activated cell sorting (FACS), 13, 177  
 Fluorescent treponemal antibody (FTA), 138, 145, 180  
 Foam cells, 157  
 Freund's adjuvant, 84  
 Frontal lobe, 18, 126, 149  
 FTA. *See* Fluorescent treponemal antibody (FTA)  
 FTA/ABS, 138, 145, 180  
 Functional MRI, 22, 23  
 Funny bone, 19

**G**

GA. *See* Glatiramer (GA)  
 GABA. *See* Gamma-aminobutyric acid (GABA)  
 GAD. *See* Glutamic acid decarboxylase (GAD)  
 Gadolinium, 32, 44, 45, 53, 59, 60, 64, 66, 141, 153, 160  
 Gadolinium-enhancing lesion, 45, 53, 74, 137, 193, 195  
 Galvani, Luigi, 15  
 Gamma-aminobutyric acid (GABA), 16, 79, 151, 162  
 Gangliosides, 95, 100, 195  
 GBS. *See* Guillain-Barré syndrome (GBS)  
 GCA. *See* Giant cell arteritis (GCA)  
 General paresis of the insane (GPI), 138  
 Gephyrin, 162  
 Giant cell arteritis (GCA), 31, 113, 144  
 Giant cells, 134  
 Glatiramer acetate (GA), 63, 74–77  
 Glia, 17, 33, 99, 122  
 Glia limitans, 27, 28, 86, 119  
 Glia limitans perivascularis, 27, 28  
 Glia limitans superficialis, 27, 28  
 Glial limitans, 119  
 Gliosis, 148, 157, 159  
 Glutamate, 16, 79  
 Glutamic acid decarboxylase (GAD), 162

Glycolipids, 95, 99, 100, 195  
 Glycosylated, 72, 192  
 GM1, 95  
 Gottron's papules, 112  
 GPCR. *See* G protein-coupled receptors (GPCR)  
 GPI. *See* General paresis of the insane (GPI)  
 G protein-coupled receptors (GPCR), 171  
 G1Qb, 100  
 Gram stain, 122–124, 187  
 Granular layer, 148  
 Granuloma, 63, 65, 134, 141  
 "Gray matter", 17, 21, 53, 126, 130, 155  
 Guillain, Georges, 93  
 Guillain-Barré syndrome (GBS), 26, 93–100, 133, 134  
 Gumma, 138

**H**

HAM. *See* HTLV-1 associated myelopathy (HAM)  
 HAND. *See* HIV-associated neurocognitive disorder (HAND)  
 Hashimoto's disease, 163  
 Hashimoto's encephalopathy, 163–164  
 Heliotrope rash, 112  
 Herniation of the brain, 127  
 Herpes simplex encephalitis (HSE), 115, 119, 125–133, 137, 187  
 Herpes simplex virus (HSV), 32, 125–128, 136, 150, 161, 175  
 Herpes zoster, 78, 136  
 Heterodimer, 76  
 Heterotetrameric, 151  
 Heuristic, 50, 59  
 High erythrocyte sedimentation rate, 113  
 Histidyl tRNA synthetases, 113, 114  
 HIV. *See* Human immunodeficiency virus (HIV)  
 HIV-associated neurocognitive disorder (HAND), 128  
 Hoffman, 22  
 Homunculus, 23  
 hs-CRP. *See* C-reactive protein (hs-CRP)  
 HSE. *See* Herpes simplex encephalitis (HSE)  
 HSV. *See* Herpes simplex virus (HSV)  
 HTLV-1. *See* Human T-lymphotropic virus-1 (HTLV-1)  
 HTLV-1 associated myelopathy (HAM), 61, 129  
 Human herpes virus 8-associated Kaposi's sarcoma, 7  
 Human immunodeficiency virus (HIV), 2, 6, 7, 31, 33, 34, 50, 58, 60, 77, 89, 113, 117, 119, 124, 125, 128–129, 136–139, 177–179, 182–183  
 Human T-lymphotropic virus-1 (HTLV-1), 13, 61  
 "Hypervariable", 10  
 Hypoglycorrachia, 124

**I**

IBM. *See* Inclusion body myositis (IBM)  
 ICH. *See* Intracerebral hemorrhage (ICH)  
 Idiopathic inflammatory myopathies (IIMs), 111–114  
 IFN- $\alpha$ . *See* Interferon- $\alpha$  (IFN- $\alpha$ )  
 IFNAR. *See* Interferon- $\alpha$ - $\beta$  receptor (IFNAR)  
 IFN- $\beta$ . *See* Interferon- $\beta$  (IFN- $\beta$ )

IFN- $\gamma$ . *See* Interferon- $\gamma$  (IFN- $\gamma$ )  
 IgSF. *See* Immunoglobulin superfamily (IgSF)  
 IIMs. *See* Idiopathic inflammatory myopathies (IIMs)  
 IL-4, 6, 87  
 IL-5, 6  
 IL-6, 6, 29, 87  
 IL-10, 6, 8, 32  
 IL-17, 6, 29, 86  
 IL-23, 86  
 IL-1 $\beta$ , 86, 87  
 Immune privilege, 27, 28  
 Immune reconstitution inflammatory syndrome (IRIS), 128, 129  
 Immune thrombocytopenic purpura (ITP), 171  
 Immunoblotting, 175, 177, 178, 180  
 Immunoglobulin superfamily (IgSF), 13, 99  
 Immunohistochemical/immunofluorescence assays, 178  
 Immunological memory, 4, 7  
 Immunoprecipitation assay, 106, 162, 181, 182  
 Immunosuppressive/immunomodulatory drugs, 152, 189, 190  
 Imuran, 77, 192–193  
 Inclusion body myositis (IBM), 111–113  
 India ink, 124  
 Infliximab, 11, 170  
 INO. *See* Internuclear ophthalmoplegia (INO)  
 iNOS. *See* Nitric oxide synthetase (iNOS)  
 Integrins, 13, 76, 77, 130, 156, 168, 197  
 Interferon- $\alpha$  (IFN- $\alpha$ ), 8, 111, 126  
 Interferon- $\alpha$ - $\beta$  receptor (IFNAR), 12, 72–74  
 Interferon- $\beta$  (IFN- $\beta$ ), 11, 12, 38, 43, 52, 63, 71–75, 111, 126, 169, 184, 195  
 Interferon- $\gamma$  (IFN- $\gamma$ ), 6, 12, 86  
 Interferons, 3, 8, 11, 72, 74, 111, 126  
 Interneurons, 18, 79  
 Internuclear ophthalmoplegia (INO), 40, 58  
 Intracerebral hemorrhage (ICH), 20  
 Intrathecal, 105, 119, 121–123, 185  
 Intravenous immunoglobulin (IVIg), 5, 97, 98, 108, 150, 158, 161, 169, 196, 197  
 Intrinsic factor, 65  
 IRIS. *See* Immune reconstitution inflammatory syndrome (IRIS)  
 Isolated optic nerves, 89  
 ITP. *See* Immune thrombocytopenic purpura (ITP)  
 IVIg. *See* Intravenous immunoglobulin (IVIg)

**J**

JCV. *See* JC virus (JCV)  
 JC virus (JCV), 7, 77, 117, 128, 130, 176, 179  
 Jerne, Niels, 168  
 JHMV, 88

**K**

Kawasaki's disease, 144  
 Kinesins, 16  
 Kohler, Georges, 168  
 Kurtzke scale, 45

**L**

LA. *See* Lupus anticoagulant (LA)  
 La antigen, 180  
 Lambert-Eaton myasthenic syndrome (LEMS), 26, 80, 104, 108, 109, 113, 148, 151, 152, 182  
 Landry de Thézillat, Jean, 93  
 Latency-associated transcripts (LATs), 126  
 LATs. *See* Latency-associated transcripts (LATs)  
 LEMS. *See* Lambert-Eaton myasthenic syndrome (LEMS)  
 Lepromatous leprosy, 134, 135  
 Leprosy, 115, 119, 133–139  
 Leukocyte immunoglobulin-like receptor (LILR), 134  
 Levator palpebrae, 107  
 Lewy bodies, 156–157  
 LFA-1, 130  
 Lightning pains, 138  
 LILR. *See* Leukocyte immunoglobulin-like receptor (LILR)  
 Limbic encephalitis, 26, 148–152, 182  
 Lipotrophy, 75  
*Listeria monocytogenes*, 122, 123  
 LMN. *See* Lower motor neuron (LMN)  
 LNB. *See* Lyme neuroborreliosis (LNB)  
 Loeffler, Friedrich, 93  
 Louis-Antoine Ranvier, 17  
 Lower motor neuron (LMN), 18–21, 24, 132  
 Lupus anticoagulant (LA), 142, 143  
 Lyme disease, 2–4, 50, 61, 97, 105, 115–122, 131, 137, 176, 179, 184, 186  
 Lyme neuroborreliosis (LNB), 13, 58, 61, 119, 178, 180, 183, 186, 190  
 Lymphoma, 7, 50, 58, 60, 147–153, 168, 169, 177, 179, 180, 194, 197  
 Lymphorrhages, 104  
 Lymphotoxin, 170

**M**

MAC. *See* Membrane attack complex (MAC)  
 Macrophages, 3, 6, 8, 10, 12, 17, 28, 30, 31, 33, 77, 85, 86, 89, 99, 100, 128, 134, 157, 158, 168, 170  
 MAG. *See* Myelin-associated glycoprotein (MAG)  
 Main immunogenic region (MIR), 110  
 Major histocompatibility complex (MHC), 3, 4, 8, 10–11, 30, 39, 99  
 MALT. *See* Mucosa-associated lymphoid tissue (MALT)  
 Mamba, 104, 172, 182  
 MBPs. *See* Myelin basic proteins (MBPs)  
 McDonald criteria, 55  
 mDCs. *See* Myeloid dendritic cells (mDCs)  
 MDEM. *See* Multiphasic disseminated encephalomyelitis (MDEM)  
 MDT. *See* Multidrug therapy (MDT)  
 Measles inclusion body encephalitis (MIBE), 88, 160  
 Mechanoreceptors, 20  
 Medial longitudinal fasciculus (MLF), 21, 40  
 Medullary decussation, 18  
 Meissner's corpuscles, 20  
 Membrane attack complex (MAC), 13, 85

- Memory, 4, 6–8, 13, 15, 18, 21, 30, 44, 128, 146, 149, 150, 155, 162, 195, 196
- Meningovascular syphilis, 60, 138
- Men who have sex with men (MSM), 60, 138
- Merkel disk receptors, 20
- Methotrexate (Rheumatrex), 11, 65, 76–78, 153, 158, 193
- MG. *See* Myasthenia gravis (MG)
- MGUS. *See* Monoclonal gammopathy of unknown significance (MGUS)
- MHC. *See* Major histocompatibility complex (MHC)
- MHV. *See* Mouse hepatitis virus (MHV)
- MIBE. *See* Measles inclusion body encephalitis (MIBE)
- Microglia, 17, 30, 31, 33, 156
- Migraine, 51, 58, 60, 65, 66
- Milstein, Cesar, 168
- MIR. *See* Main immunogenic region (MIR)
- MLF. *See* Medial longitudinal fasciculus (MLF)
- MOG. *See* Myelin oligodendrocyte protein (MOG)
- Molecular layer, 148
- Molecular mimicry, 95
- Monoclonal antibody technology, 190
- Monoclonal gammopathy, 98–99
- Monoclonal gammopathy of unknown significance (MGUS), 98, 99
- Mononeuritis multiplex, 143, 144
- Morvan's syndrome, 162
- Mouse hepatitis virus (MHV), 87, 88, 126
- MPO. *See* Anti-myeloperoxidase (MPO)
- M-protein, 99
- MPTP, 157, 158
- MPZ. *See* Myelin protein zero (MPZ)
- MSAs. *See* Myositis-specific autoantibodies (MSAs)
- MSFC. *See* Multiple sclerosis functional composite score (MSFC)
- MSM. *See* Men who have sex with men (MSM)
- MS plaque, 38, 57, 58
- MS Severity Score (MSSS), 41, 46
- MSSS. *See* MS Severity Score (MSSS)
- Mucosa-associated lymphoid tissue (MALT), 4, 30
- Multidrug therapy (MDT), 135
- Multiphasic disseminated encephalomyelitis (MDEM), 63
- Multiple myeloma, 98, 99
- Multiple sclerosis functional composite score (MSFC), 45
- Multiple system atrophy, 157
- Muscle-specific kinase (MuSK), 34, 106
- MuSK. *See* Muscle-specific kinase (MuSK)
- Mutant mice, 85, 86, 100, 114, 132
- MxA. *See* Myxovirus resistance 1 protein (MxA)
- Myasthenia gravis (MG), 12, 19, 26, 34, 35, 75, 80, 90, 103–111, 113, 172, 181, 182, 190, 193, 197, 198
- Myasthenic crisis, 106, 108, 197
- Mycobacterium leprae*, 134, 135
- Mycobacterium tuberculosis*, 61, 117, 124, 141, 187
- Mycophenolate (CellCept), 63, 108, 130, 192, 194
- Myelin, 16, 17, 24, 30–32, 37–39, 41, 52, 53, 84–86, 89, 95, 99, 100, 121, 171, 172
- Myelin-associated glycoprotein (MAG), 17, 99
- Myelin basic proteins (MBPs), 17, 26, 29, 30, 75, 84, 87, 121, 163
- Myelin oligodendrocyte protein (MOG), 26, 84–87, 90, 171–172
- Myelin protein zero (MPZ), 17
- Myelitis, 32, 33, 50, 57, 61, 95, 122, 131
- Myeloid dendritic cells (mDCs), 8
- Myoclonic jerks, 159
- Myokymia, 162
- Myopathy, 112
- Myositis-specific autoantibodies (MSAs), 111
- Myxoma, 58, 59
- Myxovirus resistance 1 protein (MxA), 74, 75, 111
- N**
- NAbs. *See* Neutralizing antibodies (NAbs)
- NAIM. *See* Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM)
- Naja naja*, 104, 110
- Natalizumab, 35, 76–77, 168, 197
- Natural killer cells (NK cells), 4, 6, 8, 197
- NCAM. *See* Neural cell adhesion molecule (NCAM)
- Neisseria meningitidis* (meningococcus), 122, 123
- Neonatal MG, 109
- Nerve conduction studies, 97, 175
- Nerve growth factor, 99
- Neural cell adhesion molecule (NCAM), 8
- Neurocysticercosis, 51, 61, 125
- Neurofibrillary tangles, 155–156
- Neurofilament proteins, 121
- Neurofilaments, 16, 121, 157
- Neurolemma, 23
- Neurologists, 15, 21, 22, 31, 37, 38, 40, 41, 43–46, 49, 50, 52, 53, 55, 57, 58, 60, 63, 64, 66, 69, 71, 72, 76, 78, 80, 88, 93, 94, 96–98, 104, 106–108, 112, 116–118, 129, 137, 141, 143–146, 149, 150, 159, 163, 175, 184, 189, 191, 193, 194
- Neuromuscular junction (NMJ), 15, 18, 19, 80, 103, 104, 106, 107, 110, 113, 151
- Neuromyelitis optica (NMO), 18, 26, 27, 33–35, 52, 62–63, 89–90, 170, 172, 180–182, 194
- Neuromyotonia, 162, 172, 182
- Neurons, 16–19, 23, 33, 79, 88, 95, 121, 122, 126, 130, 132, 136, 148, 152, 155, 156, 162, 182
- Neuropathy, 19, 24, 33, 93, 94, 97–100, 134–136, 143, 163, 196
- Neurosarcoidosis, 51, 58, 63–65, 115, 141, 142
- Neuroscience, 15, 25, 167, 172
- Neurosyphilis/Lyme disease, 2–4, 50, 54, 60–61, 97, 105, 115–122, 124, 131, 137–139, 176, 179, 180, 184, 186
- Neurotransmitters, 15–16, 19, 79, 109, 147, 156, 162
- Neurovascular unit, 20, 27, 28
- Neutralizing antibodies (NAbs), 35, 74, 75, 77, 126
- NF-kappa B. *See* Nuclear factor-kappa B (NF-kappa B)
- Nitric oxide (NO), 8
- Nitric oxide synthetase (iNOS), 8
- NK cells. *See* Natural killer cells (NK cells)
- NMDA receptor. *See* *n*-methyl-D-aspartic acid (NMDA) receptor
- n*-methyl-D-aspartic acid (NMDA) receptor, 148, 150–152

- NMJ. *See* Neuromuscular junction (NMJ)  
 NMO. *See* Neuromyelitis optica (NMO)  
 NMT. *See* Acquired neuromyotonia (NMT)  
 NNH. *See* Number needed to harm (NNH)  
 NNT. *See* Number needed to treat (NNT)  
 NO. *See* Nitric oxide (NO)  
 Nociceptors, 20  
 Nodes of Ranvier, 17, 95  
 Nonsteroidal anti-inflammatory drugs (NSAIDs),  
 64, 123, 125, 156, 158  
 Nonvasculitic autoimmune inflammatory  
 meningoencephalitis (NAIM), 163  
 Norepinephrine, 16  
 NSAIDs. *See* Nonsteroidal anti-inflammatory drugs  
 (NSAIDs)  
 Nuclear factor-kappa B (NF-kappa B), 190  
 Number needed to harm (NNH), 189  
 Number needed to treat (NNT), 189  
 Nystagmus, 21, 44
- O**
- OCBs. *See* Oligoclonal (immunoglobulin) bands (OCBs)  
 Occipital lobes, 18, 20  
 Ocrelizumab, 169, 197  
 Ofatumumab, 169  
 OIs. *See* Opportunistic infections (OIs)  
 Oligoclonal (immunoglobulin) bands (OCBs), 52, 54,  
 58–60, 62, 63, 65, 66, 143, 152, 181, 184–186  
 Oligodendrocytes, 17–18, 23, 89, 126, 130, 171  
 Omega-conotoxin, 104, 108  
 Ophthalmoplegia, 40, 58, 96, 97  
 Opiate peptides, 79  
 Opportunistic infections (OIs), 6, 7, 11, 33, 58, 60, 117,  
 128, 130, 136, 137, 195, 196  
 Opsoclonus (opsoclonus-myoclonus), 150, 152  
 Optic neuritis, 20, 40, 41, 50, 52, 57, 63, 72, 181,  
 184, 189  
 Opticospinal MS, 62  
 OraQuick, 179  
 Osteosclerotic, 99  
 Ovarian teratomas, 150, 151
- P**
- P0, 26, 99  
 P2, 26  
 p75, 99, 169  
 Paced auditory serial addition test (PASAT), 45  
 Pacinian corpuscles, 20  
 PACNS. *See* Primary angiitis of the CNS (PACNS)  
 PAMPs. *See* Pathogen-associated molecular patterns  
 (PAMPs)  
 PANDAS. *See* Pediatric autoimmune neuropsychiatric  
 disorders associated with streptococcal infection  
 (PANDAS)  
 Paramyxovirus, 160  
 Paraneoplastic cerebellar degeneration (PCD), 16, 35, 148  
 Paraneoplastic neurological disorders (PNDs),  
 147–152, 182  
 Paraneoplastic syndrome(s), 27, 63, 111, 147–153, 162,  
 180, 197  
 Parietal lobe, 18  
 Parkinson-plus complex, 156–157  
 Parkinson's disease (PD), 145, 155–158, 173  
 PAS. *See* Periodic acid-Schiff (PAS)  
 PASAT. *See* Paced auditory serial addition test (PASAT)  
 Passive transfer, 87, 89–90, 152, 162, 181  
 Pathergy test, 164  
 Pathogen-associated molecular patterns (PAMPs), 8  
 Pattern recognition receptors (PRRs), 8  
 Paucibacillary leprosy, 134  
 PCD. *See* Paraneoplastic cerebellar degeneration (PCD);  
 Programmed cell death (PCD)  
 PCR. *See* Polymerase chain reaction (PCR)  
 PD. *See* Parkinson's disease (PD);  
 Pharmacodynamics (PD)  
 pDCs. *See* Plasmacytoid dendritic cells (pDCs)  
 Pediatric autoimmune neuropsychiatric disorders  
 associated with streptococcal infection  
 (PANDAS), 26, 162  
 Pelizaeus-Merzbacher disease, 17  
 PEP. *See* Postexposure prophylaxis (PEP)  
 Pericyte, 27, 28  
 Perifascicular atrophy, 111  
 Perikaryon, 27, 28  
 Perimysium, 111  
 Perineurium, 121  
 Periodic acid-Schiff (PAS), 160  
 Peripheral lymphoid organs, 4  
 Peripheral nervous system (PNS), 15–21, 23, 24, 26,  
 27, 32, 37, 93, 99, 115, 133, 143–145, 183  
 Perivascular space, 27, 28, 32, 86  
 Pernicious anemia, 65, 160  
 Pertussis toxin, 84, 87  
 PET. *See* Positron emission tomography (PET)  
 PGL-1. *See* Phenolic glycolipid-1 (PGL-1)  
 Pharmacodynamics (PD), 69  
 Pharmacokinetics (PK), 69  
 Phase 0 study, 69, 70  
 Phase 1 study, 69–70  
 Phase 2 study, 70, 187, 188, 197  
 Phase 3 study, 8, 70, 74, 75, 78, 168, 173, 197  
 Phenolic glycolipid-1 (PGL-1), 135  
 Phospholipids, 138, 142, 180  
 Pia mater, 20, 28, 119  
 PK. *See* Pharmacokinetics (PK)  
 Placebo, 54, 70, 71, 74, 75, 167, 189, 196  
 Placebo-controlled, 70, 196  
 Plasma, 95, 97, 98, 117, 129, 152, 171, 176, 197  
 Plasma cells, 4, 8, 9, 30, 39, 54, 88, 89, 98, 99, 126,  
 134, 160, 169, 185, 186  
 Plasmacytoid dendritic cells (pDCs), 8, 111  
 Plasma exchange, 34, 97, 98, 152, 197  
 Plasmapheresis, 63, 95, 96, 108, 161, 197  
 PLP. *See* Proteolipid protein (PLP)  
 PML. *See* Progressive multifocal leukoencephalopathy  
 (PML)  
 PMNs. *See* Polymorphonuclear leukocytes (PMNs)  
 PMP<sub>22</sub>, 99, 100

PMR. *See* Polymyalgia rheumatica (PMR)  
 PNDs. *See* Paraneoplastic neurological disorders (PNDs)  
 Pneumocystis, 7, 11  
 PNS. *See* Peripheral nervous system (PNS)  
 POEMS, 99  
 Polyarteritis nodosa, 144  
 Polymerase chain reaction (PCR), 31, 35, 117, 127, 131, 136, 150, 160, 161, 175, 180, 182–183, 186, 187  
 Polymorphonuclear leukocytes (PMNs), 3, 7–8, 123–125, 187  
 Polymyalgia rheumatica (PMR), 113, 144  
 Polymyositis, 108, 111–113  
 Polyomavirus, 7  
 Pompe's disease, 167  
 Poser criteria, 55  
 Positron emission tomography (PET), 158  
 Postexposure prophylaxis (PEP), 133  
 Post-herpetic neuralgia, 136  
 Post-vaccinal encephalomyelitis, 25–29, 75, 83  
 PPMS. *See* Primary progressive MS (PPMS)  
 Predictive value, 53, 175, 176, 184, 186  
 Presenile dementia, 155  
 Primary angiitis of the CNS (PACNS), 145, 146  
 Primary APS, 142  
 Primary CNS lymphoma, 60, 147–153  
 Primary lymphoid organs, 4  
 Primary motor cortex, 18  
 Primary progressive, 37  
 Primary progressive MS (PPMS), 43, 44, 63  
 Product insert, 77  
 Programmed cell death (PCD), 3, 7, 85, 100, 149  
 Progressive multifocal leukoencephalopathy (PML), 7, 33, 60, 77, 117, 126, 129–131, 137, 168, 179, 187, 194  
 Progressive supranuclear palsy, 157  
 Projection neurons, 18, 79  
 Proteolipid protein (PLP), 17, 26, 84, 86  
 PRRs. *See* Pattern recognition receptors (PRRs)  
 Ptoisis, 106, 107  
 Purkinje cell(s), 16, 35, 148, 182  
 Purkinje layer, 148  
 Pyrimethamine, 117, 128, 137

## R

RA. *See* Rheumatoid arthritis (RA)  
 Rabies, 25–26, 29–31, 83, 85, 132–133  
 Raised intracranial pressure, 124, 127, 164  
 Randomized, 70, 72, 167, 189, 196  
 Rapid Plasma Reagin (RPR), 33, 142, 180  
 Rasmussen's encephalitis, 26, 164  
 Reaginic (antibody) tests, 180, 186  
 Recombinant DNA, 169  
 Reflexes, 15, 20–22, 51, 52, 106, 108  
 Relapse, 38, 40–46, 50, 63, 70, 71, 74, 75, 78, 88, 98, 136  
 Relapsing-remitting MS (RRMS), 42–44, 77  
 Retrovirus, 6, 61, 89, 129  
 Reverse transcriptase, 182, 186

Rheumatoid arthritis (RA), 11–12, 105, 112, 113, 115, 141, 167, 170, 171, 193  
 Rituximab, 4, 26, 35, 130, 137, 153, 168, 169, 187, 197  
 Ro antigen, 180  
 Rotenone, 157  
 RPR. *See* Rapid Plasma Reagin (RPR)  
 Ryanodine receptor, 105

## S

SAH. *See* Subarachnoid hemorrhage (SAH)  
 Saltatory, 16  
 Saltpetrière, 22, 38  
 Santiago Ramón y Cajal,  
 Sarcoidosis, 50, 63, 64, 122, 141  
 SC. *See* Sydenham's chorea (SC)  
 Schumacher criteria, 55, 59  
 Schwann, Theodor, 17  
 Schwann cells (SCs), 17, 23, 100, 134  
 "Sclérose en plaques" (SP), 39  
 SCs. *See* Schwann cells (SCs)  
 SDH. *See* Subdural hemorrhage (SDH)  
 Secondary APS, 142, 143, 145, 180  
 Secondary progressive MS (SPMS), 43, 44  
 Selectins, 13  
 Simple rabies vaccine autoimmune encephalomyelitis, 29–31, 77, 85  
 Senile plaques, 155, 156  
 Sensitivity, 40, 122, 175, 176, 181, 184, 186, 187  
 Serious adverse events, 76  
 Serology, 61, 117, 131, 177, 179, 180  
 Seronegative, 77, 106, 182  
 Serum, 10, 34, 54, 60–62, 74, 77, 95, 98, 103, 106, 115, 118, 122, 123, 129, 131, 138, 142, 145, 147, 149, 151, 158, 169, 170, 175, 176, 178–182, 185–187, 196  
 Serum protein electrophoresis (SPEP), 98, 99  
 Shingles, 33, 78, 136  
 Sjogren's syndrome, 65, 112, 143–144, 180  
 SLE. *See* Systemic lupus erythematosus (SLE)  
 Soma, 16, 27  
 Somatic hypermutation, 5, 10  
 Somatostatin, 79  
 SP. *See* "Sclérose en plaques" (SP)  
 S1P. *See* Sphingosine-1 phosphate (S1P)  
 Specificity, 3, 35, 107, 121, 122, 168, 171, 175, 176, 181, 184, 185, 187  
 SPEP. *See* Serum protein electrophoresis (SPEP)  
 Sphingosine-1 phosphate (S1P), 13, 78, 171, 195  
 Spike and wave forms, 24  
 Spinal cord, 15, 17, 18, 20, 22, 24, 26, 30, 32, 39, 44, 50–52, 54, 57, 59, 61, 62, 65, 79, 84, 86, 89, 95, 115, 129, 132, 145, 147, 153, 159, 162, 163, 181  
 Spinal cord atrophy, 42  
 SPMS. *See* Secondary progressive MS (SPMS)  
 Spontaneous activity, 162  
 SPS. *See* Stiff person syndrome (SPS)  
 SREAT. *See* Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT)



SS-A antigen, 180  
 SS-B antigen, 180  
 SSPE. *See* Subacute sclerosing panencephalitis (SSPE)  
 Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), 163  
 Stiff person syndrome (SPS), 26, 162, 196, 197  
 Stocking-glove, 19, 143  
*Streptococcus pneumoniae* (pneumococcus), 122, 123  
 Strohl, Andre, 93, 97  
 Subacute combined degeneration, 65  
 Subacute sclerosing panencephalitis (SSPE), 88, 159–160  
 Subarachnoid hemorrhage (SAH), 20, 145  
 Subcortical dementia, 63, 128  
 Subdural hemorrhage (SDH), 20  
 Substantia nigra, 156, 157  
 Sulfadiazine, 117, 137  
 Surface markers, 6, 177, 197  
 Swine-worker's neuropathy, 163  
 Sydenham's chorea (SC), 134, 161–162  
 Symptomatic therapies, 69, 78–80  
 Synapses, 15, 16  
 Systemic lupus erythematosus (SLE), 50, 58, 105, 112, 141–142, 145, 180, 191

## T

Tabes dorsalis, 138  
*Taenia solium*, 61, 187  
 Takayasu's arteritis, 144  
 Tandem gait, 22, 44  
*Tania solium*, 129  
 Tau, 156  
 TB. *See* Tuberculosis (TB)  
 T cell. *See* Thymus-derived cell (T cell)  
 T cell receptor (TCR) complexes, 4–6, 87  
 TCR. *See* T cell receptor (TCR) complexes  
 Tegument, 126  
 Temporal arteritis, 113  
 Temporal lobe, 18, 31, 32, 126, 127, 146, 150, 152  
 Tensilon test, 107  
 TGF- $\beta$ . *See* Transforming growth factor- $\beta$  (TGF- $\beta$ )  
 Th1 cells, 6, 33, 86, 87  
 Th17 cells, 6, 29, 33, 86, 87  
 Theiler's murine encephalomyelitis virus (TMEV), 87–89, 120, 132  
 Thrombocytopenia, 197  
 Thymic hyperplasia, 105, 106  
 Thymomas, 105, 106, 162  
 Thymus-derived cell (T cell), 3–8, 10, 12, 13, 26, 29–34, 38, 77, 85–87, 100, 110, 126, 129, 148, 151, 153, 157, 168, 171, 188, 191, 194–197  
 Titin, 105, 107  
 Tizanidine, 16, 79  
 TLRs. *See* Toll-like receptors (TLRs)  
 TMEV. *See* Theiler's murine encephalomyelitis virus (TMEV)  
 TNF. *See* Tumor necrosis factor (TNF)  
 TNF- $\alpha$ . *See* Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )  
 TNF- $\beta$ . *See* Tumor necrosis factor- $\beta$  (TNF- $\beta$ )  
 Tolerance, 7

Toll-like receptors (TLRs), 3, 8, 84, 134, 190  
*Toxoplasma gondii*, 117, 129, 137  
 Toxoplasmosis, 7, 33, 60, 113, 116, 117, 137  
 TPHA. *See* *Treponema pallidum* hemagglutination assay (TPHA)  
 TRAL. *See* Treatment-related acute leukemias (TRAL)  
 Transforming growth factor- $\beta$  (TGF- $\beta$ ), 12, 29, 32, 86, 87  
 Treatment-related acute leukemias (TRAL), 77  
*Treponema pallidum*, 120, 123, 124, 137, 186  
*Treponema pallidum* hemagglutination assay (TPHA), 180  
 Trigeminal ganglion, 126  
 "Trimolecular complex", 4  
*Tropheryma whipplei*, 160  
 Tropical spastic paraparesis (TSP), 61, 128, 129  
 TSP. *See* Tropical spastic paraparesis (TSP)  
 Tuberculoid leprosy, 134, 135  
 Tuberculosis (TB), 7, 51, 61–62, 78, 116, 117, 122, 125, 128, 129, 134, 135, 141, 180, 187, 188  
 Tumefactive MS, 62  
 Tumor necrosis factor (TNF), 3, 11, 12, 169–171  
 Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), 11, 12, 87, 169, 170  
 Tumor necrosis factor- $\beta$  (TNF- $\beta$ ), 6, 170  
 Type 1 interferon, 126

## U

Ulnar nerve, 19, 135  
 UMN. *See* Upper motor neuron (UMN)  
 Upper motor neuron (UMN), 20, 24, 132

## V

Valaciclovir (Valrex), 136  
 Varicella zoster virus (VZV), 33, 133–136, 144, 161, 180  
 Vasa nervorum, 144  
 Vasculitis, 31, 58, 65, 97, 113, 118, 144–146, 164  
 VCAM-1, 76  
 VDRL. *See* Venereal Disease Research Laboratory (VDRL) test  
 Venereal Disease Research Laboratory (VDRL) test, 33, 60, 138, 142, 145, 180, 186  
 Vertebrae, 18, 29  
 Very late antigen-4 (VLA-4), 76  
 VGCCs. *See* Voltage-gated calcium channels (VGCCs)  
 VGKCs. *See* Voltage-gated potassium channels (VGKCs)  
 Viral DNA polymerase, 128  
 Virchow-Robins spaces, 32  
 Visna virus, 87, 89  
 VLA-4. *See* Very late antigen-4 (VLA-4)  
 Voltage-gated calcium channels (VGCCs), 104, 108–109, 151, 172, 182  
 Voltage-gated potassium channels (VGKCs), 80, 104, 108, 151, 152, 162, 172, 182  
 VZV. *See* Varicella zoster virus (VZV)

## W

Wallerian degeneration, 23, 96  
 Wegener's granulomatosis, 65, 144, 148

Westergren sedimentation rate (WSR), 177  
Western blotting, 177, 178  
West Nile virus (WNV), 35,  
130–131, 179  
Whipple's disease, 160–161  
“White matter”, 17, 39–42, 44, 51, 53,  
55, 58–66, 118, 126, 130, 131,  
153, 164, 184

WNV. *See* West Nile virus (WNV)  
WSR. *See* Westergren sedimentation rate (WSR)

## Z

Zenapax, 197  
Ziconotide, 105  
Zoster sine herpete, 136